SG11202110376XA - Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component - Google Patents
Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective componentInfo
- Publication number
- SG11202110376XA SG11202110376XA SG11202110376XA SG11202110376XA SG11202110376XA SG 11202110376X A SG11202110376X A SG 11202110376XA SG 11202110376X A SG11202110376X A SG 11202110376XA SG 11202110376X A SG11202110376X A SG 11202110376XA SG 11202110376X A SG11202110376X A SG 11202110376XA
- Authority
- SG
- Singapore
- Prior art keywords
- same
- producing
- pharmaceutical composition
- effective component
- heteroaryl derivative
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190031269 | 2019-03-19 | ||
| KR20190134472 | 2019-10-28 | ||
| PCT/KR2020/095044 WO2020190119A1 (ko) | 2019-03-19 | 2020-03-19 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202110376XA true SG11202110376XA (en) | 2021-10-28 |
Family
ID=72521153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202110376XA SG11202110376XA (en) | 2019-03-19 | 2020-03-19 | Heteroaryl derivative, method for producing the same, and pharmaceutical composition comprising same as effective component |
Country Status (19)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102318875B1 (ko) | 2019-03-19 | 2021-11-01 | 보로노이 주식회사 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
| TW202227425A (zh) * | 2020-09-18 | 2022-07-16 | 南韓商沃若諾伊生物公司 | 雜芳基衍生物、彼之製法、及包含彼作為活性成份之藥學組成物 |
| KR20220085735A (ko) * | 2020-12-14 | 2022-06-22 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| AU2022257621A1 (en) | 2021-04-13 | 2023-11-23 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| US20240262815A1 (en) * | 2021-05-07 | 2024-08-08 | Voronoi Inc. | Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient |
| BR112022024068A2 (pt) * | 2021-05-17 | 2023-12-05 | Voronoi Inc | Compostos de derivado de heteroarila e usos dos mesmos |
| KR102563834B1 (ko) * | 2021-06-28 | 2023-08-04 | 순천대학교 산학협력단 | 세포자멸사를 유도하는 신규한 화합물 및 이를 포함하는 항암용 조성물 |
| JP2024022011A (ja) | 2022-08-05 | 2024-02-16 | 三菱マテリアル株式会社 | 切削工具 |
| CN120569380A (zh) * | 2022-11-03 | 2025-08-29 | 欧瑞克制药公司 | Egfr抑制剂的丙二酸盐和乙醇酸盐 |
| CN120035590A (zh) * | 2022-11-03 | 2025-05-23 | 株式会社沃若诺伊 | Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐 |
| CN120187724A (zh) * | 2022-11-15 | 2025-06-20 | 株式会社沃若诺伊 | 杂芳基衍生物化合物、及其用途 |
| WO2024233313A1 (en) | 2023-05-05 | 2024-11-14 | Oric Pharmaceuticals, Inc. | Egfr inhibitor for treating cancers comprising atypical egfr mutations |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2282299T3 (es) | 2000-10-20 | 2007-10-16 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos aromaticos con anillos de nitrogeno como agentes anticancerigenos. |
| WO2005026129A1 (en) | 2003-09-15 | 2005-03-24 | Gpc Biotech Ag | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| JP2008542219A (ja) | 2005-05-25 | 2008-11-27 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | 疼痛処置法 |
| US7569561B2 (en) | 2006-02-22 | 2009-08-04 | Boehringer Ingelheim International Gmbh | 2,4-diaminopyrimidines useful for treating cell proliferation diseases |
| JP2010522188A (ja) | 2007-03-20 | 2010-07-01 | スミスクライン ビーチャム コーポレーション | 化合物 |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| JP2011102241A (ja) | 2008-03-04 | 2011-05-26 | Dainippon Sumitomo Pharma Co Ltd | 新規１−アミノカルボニルピペリジン誘導体 |
| WO2011022440A2 (en) | 2009-08-17 | 2011-02-24 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| KR101401664B1 (ko) | 2011-11-15 | 2014-06-11 | 중앙대학교 산학협력단 | 신경줄기세포 분화조절제용 신규 피리미딘-2,4-디아민 유도체 및 이의 의학적 용도 |
| KR101944914B1 (ko) | 2012-01-20 | 2019-02-07 | 제노스코 | 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도 |
| US20150166591A1 (en) | 2012-05-05 | 2015-06-18 | Ariad Pharmaceuticals, Inc. | Methods and compositions for raf kinase mediated diseases |
| EP2903972B1 (en) | 2012-10-04 | 2019-12-04 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
| EP2769722A1 (en) | 2013-02-22 | 2014-08-27 | Ruprecht-Karls-Universität Heidelberg | Compounds for use in inhibiting HIV capsid assembly |
| MX355945B (es) | 2013-03-14 | 2018-05-07 | Novartis Ag | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante. |
| JP6161705B2 (ja) | 2013-08-22 | 2017-07-12 | 大鵬薬品工業株式会社 | 新規キノリン置換化合物 |
| RU2019131017A (ru) | 2013-10-21 | 2019-11-25 | Мерк Патент Гмбх | Соединения гетероарила в качестве ингибиторов btk и их применение |
| KR20150047855A (ko) | 2013-10-25 | 2015-05-06 | 한미약품 주식회사 | 단백질 카이네이즈 억제 효과를 갖는 2-사이아노-아크릴아마이드 유도체 |
| WO2015175632A1 (en) | 2014-05-13 | 2015-11-19 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| SI3157916T1 (sl) | 2014-06-19 | 2019-05-31 | Ariad Pharmaceuticals, Inc. | Heteroarilne spojine za zaviranja kinaze |
| HRP20211392T1 (hr) | 2014-10-11 | 2021-12-10 | Shanghai Hansoh Biomedical Co., Ltd. | INHIBITOR EGFR -a, I NJEGOVA PRIPREMA I PRIMJENA |
| SMT202100266T1 (it) * | 2014-10-13 | 2021-07-12 | Yuhan Corp | Composti e composizioni per modulare attività chinasiche di egfr mutante. |
| ES2699948T3 (es) | 2014-10-14 | 2019-02-13 | Sunshine Lake Pharma Co Ltd | Compuestos de heteroarilo sustituido y métodos de uso |
| WO2016105525A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Novel pyrimidines as egfr inhibitors and methods of treating disorders |
| US10329277B2 (en) | 2015-07-16 | 2019-06-25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(3-methyl-2-OXO-2,3-dihydro-1h-benzo[d]imidazol-1-yl)pyrimidin-2-yl)amino)phenyl)acrylamide hydrochloride as an inhibitor of epidermal growth factor receptor activity |
| CN106478607B (zh) | 2015-08-28 | 2019-05-24 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| JP6606278B2 (ja) * | 2015-08-31 | 2019-11-13 | ウーシー ショアンリャン バイオテクノロジー カンパニー，リミティド | ２−アリールアミノピリジン、ピリミジン又はトリアジン誘導体及びその製造方法と使用 |
| CN108602809B (zh) | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| WO2017120429A1 (en) | 2016-01-07 | 2017-07-13 | CS Pharmasciences, Inc. | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| US11203576B2 (en) | 2016-03-11 | 2021-12-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Aurora kinase and Janus kinase inhibitors for prevention of graft versus host disease |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| JP7028900B2 (ja) | 2017-06-13 | 2022-03-02 | ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー | アミノピリミジン化合物、その調製方法、およびその使用 |
| US20200131176A1 (en) * | 2017-07-05 | 2020-04-30 | Cs Pharmatech Limited | Selective inhibitors of clinically important mutants of the egfr tyrosine kinase |
| EP3700904B1 (en) | 2017-10-24 | 2023-07-19 | Bayer AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN108191774B (zh) | 2018-01-31 | 2022-05-24 | 中国药科大学 | 一类杂环化合物、其制备方法和用途 |
| TWI798334B (zh) | 2018-01-31 | 2023-04-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | Ｅｒｂｂ／ｂｔｋ抑制劑 |
| KR102782739B1 (ko) | 2018-03-13 | 2025-03-20 | 보로노이 주식회사 | 2,4,5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2019177374A1 (ko) | 2018-03-13 | 2019-09-19 | 포로노이바이오 주식회사 | 2, 4, 5-치환된 피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 또는 염증질환의 예방 또는 치료용 약학적 조성물 |
| BR112020023107A2 (pt) | 2018-05-14 | 2021-02-02 | Ariad Pharmaceuticals, Inc. | sais farmacêuticos de derivados de pirimidina e método de tratamento de distúrbios |
| CN109280048A (zh) | 2018-11-16 | 2019-01-29 | 江西科技师范大学 | 一种含取代苯基丙烯酰胺结构的嘧啶类化合物及其应用 |
| CN109608394A (zh) | 2018-12-03 | 2019-04-12 | 湖南大学 | 氮杂芳胺类化合物的合成方法和氮杂芳胺类化合物 |
| KR102318875B1 (ko) * | 2019-03-19 | 2021-11-01 | 보로노이 주식회사 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| US12157730B2 (en) | 2019-03-19 | 2024-12-03 | Voronoi Inc. | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component |
-
2020
- 2020-03-19 KR KR1020200033737A patent/KR102318875B1/ko active Active
- 2020-03-19 PT PT207740598T patent/PT3943491T/pt unknown
- 2020-03-19 SI SI202030641T patent/SI3943491T1/sl unknown
- 2020-03-19 AU AU2020240382A patent/AU2020240382B2/en active Active
- 2020-03-19 CN CN202080022186.4A patent/CN113993866B/zh active Active
- 2020-03-19 NZ NZ781366A patent/NZ781366A/en unknown
- 2020-03-19 DK DK20774059.8T patent/DK3943491T3/da active
- 2020-03-19 WO PCT/KR2020/095044 patent/WO2020190119A1/ko active IP Right Grant
- 2020-03-19 US US17/440,630 patent/US12152021B2/en active Active
- 2020-03-19 JP JP2022504023A patent/JP7109013B2/ja active Active
- 2020-03-19 FI FIEP20774059.8T patent/FI3943491T3/fi active
- 2020-03-19 EP EP20774059.8A patent/EP3943491B1/en active Active
- 2020-03-19 MA MA055380A patent/MA55380A/fr unknown
- 2020-03-19 MX MX2021011160A patent/MX2021011160A/es unknown
- 2020-03-19 CA CA3134261A patent/CA3134261A1/en active Pending
- 2020-03-19 CN CN202211226875.4A patent/CN115838369A/zh active Pending
- 2020-03-19 BR BR112021018704-9A patent/BR112021018704B1/pt active IP Right Grant
- 2020-03-19 CN CN202210215237.6A patent/CN114605400B/zh active Active
- 2020-03-19 SG SG11202110376XA patent/SG11202110376XA/en unknown
-
2021
- 2021-09-19 IL IL286471A patent/IL286471B2/en unknown
- 2021-10-15 ZA ZA2021/07889A patent/ZA202107889B/en unknown
- 2021-10-21 KR KR1020210141386A patent/KR102564533B1/ko active Active
- 2021-11-08 US US17/521,711 patent/US11466000B2/en active Active
-
2022
- 2022-07-07 JP JP2022109721A patent/JP7394298B2/ja active Active
- 2022-08-01 AU AU2022211789A patent/AU2022211789B2/en active Active
-
2023
- 2023-01-11 IL IL299831A patent/IL299831B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL286471A (en) | The heteroaryl derivative, a method for its production and a pharmaceutical preparation containing it as an effective ingredient | |
| SG11202105850YA (en) | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof | |
| EP3511314A4 (en) | SYSTEM FOR PRODUCING ESTER COMPOSITION AND METHOD FOR PRODUCING ESTER COMPOSITION USING SAME | |
| EP3312177A4 (en) | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same | |
| EP3687540A4 (en) | HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF | |
| PT3580208T (pt) | Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro | |
| EP3808751A4 (en) | CAMPTOTHECIN DERIVATIVE, METHOD OF PRODUCTION THEREOF AND APPLICATION THEREOF | |
| EP3908277A4 (en) | HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHODS OF USE THEREOF | |
| EP3838898C0 (en) | ISOINDOLIN-1-ONE DERIVATIVE, PROCESS FOR PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE PREVENTION OR TREATMENT OF CANCER | |
| IL286733A (en) | Compound, pharmaceutical composition and method for modulating dux4 expression | |
| EP3689859A4 (en) | PROCESS FOR MANUFACTURING OXASPIROCYCLE DERIVATIVES AND INTERMEDIATE THEREOF | |
| IL285204A (en) | Formulation of apavicin, method for its preparation | |
| SG11202107848TA (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| EP3805212A4 (en) | 3-OXAZOLINONE COMPOUND, METHOD FOR PREPARING THEREOF, AND PHARMACEUTICAL USE THEREOF | |
| IL251456A0 (en) | Substances with agonist activity for gpr119, processes for their preparation and preparations containing them | |
| EP3303320A4 (en) | Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same | |
| HK40090980A (en) | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | |
| HK40074494B (en) | Heteroaryl derivative, method for producing same, and pharmaceutical composition comprising same as effective component | |
| SG11202111558VA (en) | Crystalline form of compound, method for preparing the same, pharmaceutical composition and use | |
| EP3886582A4 (en) | SYNERGISTIC PRESERVATIVE COMPOSITIONS, METHOD OF MAKING THEREOF AND METHOD OF USE THEREOF | |
| HK40104040A (en) | Compound, pharmaceutical composition, method for preparing same and method for treating disease | |
| HK40115830A (en) | Pharmaceutical composition, package and method for producing the same | |
| HK40033945B (en) | Immunogenic composition and method for producing the same | |
| GB201805951D0 (en) | Pharmaceutical composition and method for manufacturing the same | |
| HK40006665B (en) | Novel benzylamide compound, method for producing the same, and miticide |